SEARCH

SEARCH BY CITATION

Immunoglobulin A (IgA), as the major class of antibody present in the mucosal secretions of most mammals, represents a key first line of defence against invasion by inhaled and ingested pathogens at the vulnerable mucosal surfaces. IgA is also found at significant concentrations in the serum of many species, where it functions as a second line of defence mediating elimination of pathogens that have breached the mucosal surface. Receptors specific for the Fc region of IgA, FcαR, are key mediators of IgA effector function and studies described in this issue of Immunology by Rogers and colleagues1 add to a growing appreciation of IgA function in different species.

Although IgA appears to share common protective functions in the different species where it is found, variations in gene number, allotypes and molecular forms have been noted. Humans, chimpanzees, gorillas and gibbons have two IgA heavy constant region (Cα) genes which give rise to the two subclasses, IgA1 and IgA2,2,3 whereas most other species examined (orangutan, rhesus and cynomolgus macaques, cow, horse, pig, dog, mouse, rat, echnida and possum) have just one Cα gene.2,4–11 An interesting exception is provided by the rabbit which has 13 Cα genes,12 of which 11 appear to be expressed.13 Single IgA genes may also assumed to be present in most birds as they have been described in chickens and ducks, considered to be among the most primitive extant birds.14,15

The two IgA subclasses in hominoid primates, having arisen through gene duplication, share considerable sequence similarity. The major difference between IgA1 and IgA2 resides in the hinge region that lies between the two Fab arms and the Fc region. IgA1 features a very extended hinge due to the insertion of a duplicated stretch of amino acids, which is lacking in IgA2. The longer hinge in IgA1 may have evolved to offer advantages in antigen recognition by allowing higher avidity bivalent interactions with distantly spaced antigens.16,17 However, this extended reach is accompanied by an increased vulnerability to proteolytic attack. Indeed, a number of important pathogenic bacteria, such as Streptococcus pneumonaie, Neisseria meningitidis and Haemophilus influenzae, have evolved enzymes independently that cleave specifically in the IgA1 hinge.18 The ability of these IgA1 proteases to compromise IgA function is thought to facilitate the initiation of infection at mucosal surfaces by these microorganisms.

Allelic variation in IgA has been investigated in some species but remains to be investigated in many others. In humans, there are two (or possibly three19) alleles of the IgA2 subclass. Rhesus macaque IgA also displays allelic polymorphism,4,20 while restriction fragment length polymorphism (RFLP) evidence points towards the existence of bovine IgA and equine IgA allotypes.21 Mouse IgA exists in different allelic forms that vary particularly in their hinge regions.22 The two allelic variants of pig IgA differ similarly in the hinge region.21

The serum distribution of the different molecular forms of IgA also varies from species to species. IgA has the capacity to form dimers, in which two monomer units, each comprising two heavy chains and light chains, are arranged in an end-to-end configuration stabilized by disulphide bridges and incorporation of J (joining) chain.23,24 For reasons that remain unclear, serum IgA is chiefly monomeric in humans (and presumably in other primates), but mainly dimeric in other animals.

Dimeric IgA, produced locally at mucosal sites, is transported across the epithelial cell boundary and out into the secretions by interaction with the polymeric immunoglobulin receptor (pIgR). During this process the pIgR is cleaved and the major fragment, termed secretory component (SC), becomes covalently attached to the IgA dimer. Thus SC is an integral part of the IgA molecule released into the secretions (secretory IgA) and is thought to help protect the antibody against degradation. Although IgA is the predominant Ig in the majority of secretions in most mammals, the proportion of IgA in colostrum and milk varies between species, reflecting the development of differing modes of transfer of antibodies from mother to offspring. In primates and rodents, IgG is transferred selectively across the placenta, and the chief Ig in colostrum is IgA. The serum antibody of the newborn is supplemented further in rodents with IgG derived from the colostrum that is actively transported across the neonatal gut by the neonatal Fc receptor (FcRn). In contrast, large mammals such as horses, pigs and cows, lack transplacental transfer of IgG. Instead, IgG is the major immunoglobulin class in colostrum and is absorbed across the neonatal gut in a brief time period prior to ‘closure’ at around 12 hr after birth. In the colostrum of these species IgA content is low, and it remains low in milk in cattle. However, in pigs and horses IgA is the major antibody in milk.21

From the above, it is clear that there are significant variations within the IgA systems of different species. A further important consideration relates to the triggering of IgA effector function through interaction with FcαR. The human FcαR (now termed FcαRI or CD89) was the first to be cloned and characterized (reviewed in Monteiro & van de Winkel25). Ligation of FcαRI by bacterial and viral targets coated in IgA initiates potent responses such as phagocytosis, respiratory burst and release of cytokines, to bring about elimination of the invading microorganism.25 Although FcαRI displays homology to other human FcR specific for IgG and IgE, namely FcγRI, FcγRII, FcγRIII and FcɛRI, it is a more distantly related member of the family. Indeed, it resembles more closely a family of receptors including natural killer cell Ig-like receptors (KIR) and NKp46 receptors, the genes of which flank that of FcαRI in the leukocyte Ig-like receptor cluster (LRC) on chromosome 19. In contrast, the FcγR and FcɛRI genes are clustered on chromosome 1.

While information on human FcαRI has amassed steadily, the FcαR systems in other species are not yet understood fully. The search for FcαR orthologues centred initially on the mouse, but despite exhaustive efforts no mouse equivalent was found. Unexpectedly, an IgG Fc receptor in cattle termed Fcγ2R was found to more closely resemble human FcαRI than human FcγR.26 However, it is only in the last few months that the first true orthologues of human FcαRI have been described in rats27 and cattle.28 The family is now extended further with the description of FcαR in Rhesus macaques.1

The similarity between all the receptors suggests that the FcαR gene may have been generally conserved in mammals. The chromosomal position of the receptor gene adjacent to killer cell receptor genes is a consistent feature in all species investigated. In humans, rats and cattle, the FcαR genes cluster with KIR and NKp46 genes (or their homologues).27–29 Rats are closer to mice in evolutionary terms than to gerbils and hamsters, but in Southern blots a rat FcαR probe showed hybridizing bands in gerbils and hamsters but not in mice.27 This finding, along with the fact that searches of the mouse genome database with known FcαR sequences fail to identify matches, indicates that the mouse genome has lost the FcαR gene. Studies on mouse killer cell receptors have thrown light on how this may have occurred. Mice were thought earlier to lack KIR-like genes but they have been found recently.30,31 Surprisingly, these are located on the X chromosome rather than within the murine LRC on chromosome 7 to which the mouse NKp46 gene localizes. Thus the mouse probably lost the FcαR gene during a translocation event when its KIR-like genes moved from the LRC to the X chromosome. It seems likely that mice have evolved alternative receptors for IgA. A receptor specific for both IgA and IgM Fc (Fcα/µR) has been characterized on B cells and macrophages32 and there is evidence that mouse IgA can trigger mouse neutrophils.33

Interest in the potential of antibody-based therapeutic approaches centred on IgA/FcαR continues to mount,34,35 and results with tumour and infectious targets are very encouraging.36–40 In order to assess readily the efficacy of such reagents, and also to understand better IgA-related diseases such as IgA nephropathy, suitable animal models could prove highly valuable. There are limitations with mouse models in this context, due to the lack of both FcαR orthologue and monomeric serum IgA. An increased knowledge of the IgA effector systems in other mammals will facilitate the development of appropriate models. Rhesus macaques are already used widely as models in numerous infectious diseases, including the simian immunodeficiency virus (SIV) or simian-human immunodeficiency virus (SHIV) model in AIDS research.41 The study of Rogers and colleagues1 will further the possibilities for macaque models relevant to the IgA system.

Acknowledgment

  1. Top of page
  2. Acknowledgment
  3. References

J.M.W. thanks the Leukaemia Research Fund for support.

References

  1. Top of page
  2. Acknowledgment
  3. References
  • 1
    Rogers KA, Scinicariello F, Attanasio R. Identification and characterization of macaque CD89 (IgA Fc receptor). Immunology 2004; 113: 17886.
  • 2
    Kawamura S, Tanabe H, Watanabe Y, Kurosaki K, Saitou N, Ueda S. Evolutionary rate of immunoglobulin alpha noncoding region is greater in hominoids than in Old World monkeys. Mol Biol Evol 1991; 8: 74352.
  • 3
    Kawamura S, Saitou N, Ueda S. Concerted evolution of the primate immunoglobulin α-gene through gene conversion. J Biol Chem 1992; 267: 735967.
  • 4
    Scinicariello F , Attanasio R. Intraspecies heterogeneity of immunoglobulin α-chain constant region genes in rhesus macaques. Immunology 2001; 103: 4418.DOI: 10.1046/j.1365-2567.2001.01251.x
  • 5
    Brown WR, Rabbani H, Butler JE, Hammarstrom L. Characterization of the bovine Cα gene. Immunology 1997; 91: 16.
  • 6
    Wagner B, Greiser-Wilke I, Antczak DF. Characterization of the horse (Equus caballus) IGHA gene. Immunogenetics 2003; 55: 55260.DOI: 10.1007/s00251-003-0617-2
  • 7
    Brown WR, Butler JE. Characterization of a Cα gene of swine. Mol Immunol 1994; 31: 63342.
  • 8
    Patel M, Selinger D, Mark GE, Hickey GJ, Hollis GF. Sequence of the dog immunoglobulin alpha and epsilon constant region genes. Immunogenetics 1995; 41: 2826.
  • 9
    Tucker PW, Slightom JL, Blattner FR. Mouse IgA heavy chain gene sequence: implications for evolution of immunoglobulin hinge exons. Proc Natl Acad Sci USA 1981; 78: 76848.
  • 10
    Belov K, Zenger KR, Hellman L, Cooper DW. Echidna IgA supports mammalian unity and traditional Therian relationship. Mamm Genome 2002; 13: 65663.
  • 11
    Belov K, Harrison GA, Cooper DW. Molecular cloning of the cDNA encoding the constant region of the immunoglobulin A heavy chain (Cα) from a marsupial: Trichosurus vulpecula (common brushtail possum). Immunol Lett 1998; 60: 16570.
  • 12
    Burnett RC, Hanly WC, Zhai SK, Knight KL. The IgA heavy-chain gene family in rabbit. cloning and sequence analysis of 13 Cα genes. EMBO J 1989; 8: 40417.
  • 13
    Spieker-Polet H, Yam PC, Knight KL. Differential expression of 13 IgA-heavy chain genes in rabbit lymphoid tissues. J Immunol 1993; 150: 545765.
  • 14
    Mansikka A, Chicken Ig, AH chains. Implications concerning the evolution of H chain genes. J Immunol 1992; 149: 85561.
  • 15
    Magor KE, Warr GW, Bando Y, Middleton DL, Higgins DA. Secretory imune system of the duck (Anas platyrhynchos). Identification and expression of the genes encoding IgA and IgM heavy chains. Eur J Immunol 1998; 28: 10638.DOI: 10.1002/(SICI)1521-4141(199803)28:03<1063::AID-IMMU1063>3.3.CO;2-F
  • 16
    Boehm MK, Woof JM, Kerr MA, Perkins SJ. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling. J Mol Biol 1999; 286: 142147.
  • 17
    Furtado PB, Whitty PW, Robertson A, Eaton JT, Almogren A, Kerr MA, Woof JM, Perkins SJ. Solution structure determination of monomeric human IgA2 by X-ray and neutron scattering, analytical ultracentrifugation and constrained modelling: a comparison with monomeric human IgA1. J Mol Biol 2004; 338: 92141.DOI: 10.1016/j.jmb.2004.03.007
  • 18
    Senior BW, Loomes LM, Kerr MA. Microbial IgA proteases and virulence. Rev Med Microbiol 1991; 2: 2007.
  • 19
    Chintalacharuvu KR, Raines M, Morrison SL. Divergence of human α-chain constant region gene sequences. A novel recombinant α2 gene. J Immunol 1994; 152: 5299304.
  • 20
    Scinicariello F, Engleman CN, Jayashankar L, McClure HM, Attanasio R. Rhesus macaque antibody molecules: sequence and heterogeneity of alpha and gamma constant regions. Immunology 2004; 111: 6674.DOI: 10.1111/j.1365-2567.2004.01767.x
  • 21
    Butler JE. Immunoglobulin diversity, B-cell and antibody repertoire development in large farm animals. Rev Sci Tech Off Int Epiz 1998; 17: 4370.
  • 22
    Phillips-Quagliata JM. Mouse IgA allotypes have major differences in their hinge regions. Immunogenetics 2002; 53: 10338.DOI: 10.1007/s00251-002-0434-z
  • 23
    Bastian A, Kratzin H, Eckart K, Hilschmann N. Intra- and interchain disulfide bridges of the human J chain in secretory immunoglobulin A. Biol Chem Hoppe Seyler 1992; 373: 125563.
  • 24
    Krugmann S, Pleass RJ, Atkin JD, Woof JM. Structural requirements for assembly of dimeric IgA probed by site-directed mutagenesis of J chain and a cysteine residue of the α-chain CH2 domain. J Immunol 1997; 159: 2449.
  • 25
    Monteiro RC, Van De Winkel JGJ. IgA Fc receptors. Annu Rev Immunol 2003; 21: 177204.DOI: 10.1146/annurev.immunol.21.120601.141011
  • 26
    Zhang G, Young JR, Tregaskes CA, Sopp P, Howard CJ. Identification of a novel class of mammalian Fc gamma receptor. J Immunol 1995; 155: 153441.
  • 27
    Maruoka T, Nagata T, Kasahara M. Identification of the rat IgA Fc receptor encoded in the leukocyte receptor complex. Immunogenetics 2004; 55: 7126.DOI: 10.1007/s00251-003-0626-1
  • 28
    Morton HC, Pleass RJ, Storset AK, Dissen E, Williams JL, Brandtzaeg P, Woof JM. Cloning and characterization of an IgA Fc receptor from cattle (bFcαR). Immunology 2004; 111: 20411.DOI: 10.1111/j.0019-2805.2003.01808.x
  • 29
    Martin AM, Kulski JK, Witt C, Pontarotti P, Christiansen FT. Leukocyte Ig-like receptor complex (LRC) in mice and men. Trends Immunol 2002; 23: 818.DOI: 10.1016/S1471-4906(01)02155-X
  • 30
    Welch AY, Kasahara M, Spain LM. Identification of the mouse killer immunoglobulin-like receptor-like (Kirl) gene family mapping to chromosome X. Immunogenetics 2003; 54: 78290.
  • 31
    Hoelsbrekken SE, Nylenna O, Saether PC, Slettedal IO, Ryan JC, Fossum S, Dissen E. Molecular cloning of a killer cell Ig-like receptor in the mouse and rat. J Immunol 2003; 170: 225963.
  • 32
    Shibuya A, Sakamoto N, Shimizu Y et al. Fcα/µ receptor mediates endocytosis of IgM-coated microbes. Nat Immunol 2000; 1: 4416.DOI: 10.1038/80886
  • 33
    Kerr MA, Mackenzie S, Gilbert AD. Measurement of respiratory burst induced in murine polymorphonuclear neutrophils by murine IgA. J Dent Res 1997; 74: 846.
  • 34
    Corthésy B. Recombinant immunoglobulin A: powerful tools for fundamental and applied research. Trends Biotechnol 2002; 20: 6571.DOI: 10.1016/S0167-7799(01)01874-1
  • 35
    Dechant M, Valerius T. IgA antibodies for cancer therapy. Crit Rev Oncol Hematol 2001; 39: 6977.
  • 36
    Valerius T, Stockmeyer B, Van Spriel AB et al. FcαRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997; 90: 448592.
  • 37
    Deo YM, Sundarapandiyan K, Keler T, Wallace PK, Graziano RF. Bispecific molecules directed to the Fc receptor for IgA (FcαRI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J Immunol 1998; 160: 167786.
  • 38
    Stockmeyer B, Dechant M, Van Egmond M et al. Triggering Fcα-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 2000; 165: 595461.
  • 39
    Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, Van De Winkel JGJ, Valerius T. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002; 100: 457480.
  • 40
    Tacken PJ, Hartshorn KL, White MR, Van Kooten C, Van De Winkel JG, Reid KB, Batenburg JJ. Effective targeting of pathogens to neutrophils via chimeric surfactant protein D/anti-CD89 protein. J Immunol 2004; 172: 493440.
  • 41
    Hirsch VM, Lifson JD. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. Adv Pharmacol 2000; 49: 43777.